Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 2302032A

Drug Profile

GSK 2302032A

Alternative Names: GSK2302032A; PRAME Antigen Specific Cancer Immunotherapeutic - NSCLC; PRAME-ASCI-Non-small cell lung cancer

Latest Information Update: 18 Jul 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer

Most Recent Events

  • 01 Aug 2016 GSK completes a phase-II clinical trial in Non-small cell lung cancer (Adjuvant therapy) Estonia, France, Germany, Japan, South Korea, Poland, Russia, United Kingdom and USA (NCT01853878)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer in France (IM, Injection)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer in Germany (IM, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top